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Abstract
Endometrial cancer is the only gynecologic malignancy with a rising incidence and mortality. While cure is routinely
achieved with surgery alone or in combination with adjuvant pelvic radiotherapy when disease is confined to the
uterus, patients with metastatic or recurrent disease exhibit limited response rates to cytotoxic chemotherapy, targeted
agents, or hormonal therapy. Given the unmet clinical need in this patient population, exploration of novel therapeutic
approaches is warranted, and attention is turning to immunomodulation of the tumor microenvironment. Existing
evidence suggests that endometrial cancer is sufficiently immunogenic to be a reasonable candidate for active and/or
passive immunotherapy. In this review, we critically examine what is known about the microenvironment in
endometrial cancer and what has been learned from preliminary immunotherapy trials that enrolled endometrial
cancer patients, encouraging further attempts at immunomodulation in the treatment of aggressive forms of this
disease.
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Background
As the most common cancer of the female genital tract,
it is estimated that in 2015 endometrial cancer will be
diagnosed in over 54,000 women and will be responsible
for over 10,000 deaths in the United States [1]. At the
time of diagnosis, 67 % of women have disease confined
to the uterus and an associated 5-year survival rate of
95 % [1]. In contrast, the 8 % of patients with distant
metastases at the time of diagnosis have a 5-year survival
rate of 17 % [1] and face the prospect of cytotoxic
chemotherapy (primarily with taxanes, anthracyclines,
and platinum drugs) with limited response.
Since the completion of Gynecologic Oncology Group
(GOG) protocol 177, which explored the triplet regimen
of paclitaxel, doxorubicin and cisplatin (TAP) in patients
with advanced stage and recurrent endometrial cancer,
demonstrating an overall response rate of 57 % and me-
dian overall survival of 15.3 months, results have been
clinically disappointing. Furthermore, the toxicity associ-
ated with the 3-drug regimen has limited its clinical util-
ity [2]. The GOG, in the 229 queue, has evaluated a
series of targeted agents [3–9] including bevacizumab
(229E), aflibercept (229 F), bevacizumab/temsirolimus
(229G), AZD6244 (229H), brivanib (229I), cediranib
(229 J), AMG386 (229 L) and BIBF 1120 (229 K) with
modest overall response rates, ranging from 0 % -
24.5 % (Table 1). Hormonal therapy is better tolerated
but results in response rates between 18 % and 34 %
[10]. With taxanes alone showing response rates of
greater than 20 % in select patients (taxane-naïve) with
recurrent disease [11, 12], effective second-line chemo-
therapeutic options are limited. Given the above unmet
clinical need, exploration of novel therapeutic ap-
proaches is warranted in this patient population.
Within cancer drug development, a shift in focus from
the tumor cell itself to the tumor microenvironment
(TME) has been gradually gaining momentum. This shift
has come with the recognition of the limitations of tar-
geted therapy, which act by blocking essential biochem-
ical pathways or mutant proteins that are required for
tumor cell growth and survival. The ideal use of targeted
therapies is in cancers with a single dominant driver mu-
tation and a small mutational load, the classic example
being chronic myeloid leukemia (CML) bearing the
Philadelphia chromosome (bcr-abl gene translation)
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[13]. Most cancers, however, exhibit genetic heterogen-
eity. Fortunately, this same genetic heterogeneity that
translates into limited therapeutic responses with tar-
geted agents, may result in enhanced tumor immuno-
genicity, provoking an adaptive immune response. This
concept of tumor immunogenicity is well appreciated
for its role in determining the efficacy of immunother-
apy [14]. Currently, our understanding of the somatic
mutational load in endometrial cancer is evolving, and
work is being done to identify the correlation between
mutations and immunogenicity [15].
In this review, we critically examine what is known
about the microenvironment in endometrial cancer and
what has been learned from preliminary immunotherapy
trials that enrolled endometrial cancer patients, encour-
aging further attempts at immunomodulation in the
treatment of aggressive forms of this disease.
Characterizing the Tumor Microenvironment
Exploiting the immune system in cancer therapeutics re-
lies on characterizing its components within the TME.
This has proven to be a major endeavor, given the differ-
ences in the immune cell composition between different
types of cancer, as well as between cancers of the same
type. This diversity results from the phenotypic and
functional plasticity of immune cells, which are respon-
sible for a diverse set of tasks within the immune sys-
tem’s overarching objective of host protection and tissue
homeostasis. In both innate and adaptive immunity, im-
mune cells are simultaneously responsible for promoting
host defense while limiting collateral tissue damage. It is
well established that the microenvironment has the cap-
acity to regulate the phenotype and function of differen-
tiated myeloid or lymphoid cells at the level of their
progenitors, during their lineage-specific differentiation,
and after they have matured into the fully differentiated
cell types [16]. This plasticity lends support to the idea
that differentiated hematopoietic cells should be viewed
on a dynamic continuum rather than in distinct
subcategories.
The lack of success in developing a cohesive picture of
endometrial cancer on the molecular level may be ex-
plained, in part, by the fluctuations in immune cell com-
position of the endometrium that result from hormonal
influences. As described in two recent reviews [17, 18],
the immune system within the endometrium faces a
unique challenge; it must be competent enough to pro-
vide protection against sexually transmitted pathogens
while being permissive enough to allow the development
of an allogeneic fetus. As such, this site within the fe-
male reproductive tract has evolved in such a way that
sex hormones precisely regulate immune function to ac-
complish both tasks. The number of macrophages, neu-
trophils, and natural killer (NK) cells steadily increase
throughout the menstrual cycle and are most abundant
before menstruation, perhaps reflecting their role in the
breakdown of the endometrium and in host defense dur-
ing disruption of the mucosal barrier. Similarly, adaptive
immune cells, which are present in the endometrium as
unique aggregates consisting of a B-cell core surrounded
by T cells and an outer halo of macrophages, increase in
number throughout the proliferative phase and tempor-
arily lose cytotoxic capabilities during the secretory
phase, when conception may occur. These findings high-
light the exceptional responsiveness of the immune sys-
tem to hormonal fluctuations in this particular
microenvironment.
In regards to the composition of the TME and corre-
sponding associations with prognosis, endometrial can-
cer has been relatively understudied in comparison to
other malignancies. In ovarian cancer, for example, it is
well established that the presence of intraepithelial
tumor infiltrating lymphocytes (TILs) is a robust pre-
dictor of a more favorable outcome, as demonstrated in
a recent meta-analysis including 10 studies [19]. Early
clinicopathologic studies were conflicting in regards to
whether TILs were more common in low-grade [20] vs.
high-grade endometrial cancers [21] and whether the lo-
cation of TILs has prognostic implications. A perivascu-
lar lymphocytic infiltrate has been shown to correlate
with poor overall survival (OS) on univariate analysis
Table 1 Clinical end points in the GOG 229 queue
GOG Trial N ORR PFS > 6mo Median PFS (mo.) Median OS (mo.)
229 N [7] 28 0 % 11 % 2.1 9.4
229 K [6] 37 9.4 % 22 % 3.3 10.1
229 I [8] 45 18.6 % 30 % 3.3 10.7
229 G* [5] 53 24.5 % 47 % 5.6 16.9
229 F* [4] 49 8.9 % 40 % 2.9 14.6
229 E [3] 56 13.5 % 40.4 % 4.2 10.5
229 J [9] 53 12.5 % 29 % 3.5 12.5
*Significant Grade 3/4 adverse events were encountered on these studies preventing subsequent development of a phase 3 trial; GOG = gynecologic oncology
group; ORR = overall response rate; PFS = progression free survival; OS = overall survival
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[22] while an intraepithelial lymphocytic infiltrate at the
invasive border [23] has been shown to correlate with
improved OS on multivariate analysis. On the whole,
given the limited data set, and study heterogeneity, com-
paring studies to draw meaningful conclusions has been
problematic.
Contemporary studies have not only examined the
presence of intra-tumoral, cytotoxic T cells but also the
ratio of CD8+ TILs to regulatory T cells (Tregs: CD4+
CD25+ FOXP3+), which are well known for their
physiologic role in peripheral tolerance and their patho-
logical role in antitumor immunity. After adjusting for
well known prognostic factors in multivariate analysis,
de Jong and colleagues [24] found that the presence of
high numbers of CD8+ TILs was an independent pre-
dictor of increased OS (whole cohort and type II) and
that the presence of a high CD8+/FoxP3+ ratio was an
independent predictor of increased disease-free survival
(DFS) in type I, though not type II, endometrial cancer
patients. The importance of the ratio of CD8+ to FoxP3
+ T cells to DFS was confirmed in an additional study
that did not stratify by tumor type [25]. The amount of
intra-tumoral Tregs alone has not been shown to impact
recurrence and survival curves [26, 27], though a statisti-
cally significant correlation has been shown between the
presence of Tregs and tumor stage, grade, and presence
of myometrial invasion [28].
There appears to be a better understanding of the role
of myeloid cells, in comparison to lymphoid cells, in
endometrial pathology. While myeloid-derived suppres-
sor cells (MDSCs) have been detected in tumor speci-
mens [29], tumor associated macrophages (TAMs) have
been consistently identified as the dominant contributor
to a pro-tumorigenic environment [30]. TAM density,
particularly within the stromal compartment, has been
shown to steadily increase with disease progression from
precancerous endometrial lesions (various forms of
hyperplasia) to endometrial cancer [31, 32]. The pres-
ence of TAMs has been repeatedly correlated to aggres-
sive features within the primary tumor, specifically
higher stage and grade and the presence of lymphovas-
cular and myometrial invasion [27, 33–36]. The results
of only one study, containing a small and heterogeneous
cohort of type I and II carcinomas, has differed from
these consistent findings [31]. Additionally, the presence
of TAMs has been strongly associated with pelvic lymph
node metastases [27, 32, 35, 37] and an angiogenic pro-
file [34–36, 38, 39].
Recently, Kubler and colleagues [27] were the first to
demonstrate that TAM density is an independent prog-
nostic factor for recurrence-free survival, finding that a
high density compared to a low density of TAMs in-
creased the risk of recurrence by a factor of 8.3. In their
study, a significant relationship between the presence of
TAMs and overall survival was found on univariate ana-
lysis but not on multivariate analysis. They hypothesize
that detecting significance may not have been possible in
this cohort of patients of mostly early stage disease due
to the length of follow-up and the treatment of relapsed
cases with curative intent. These same factors may ex-
plain why previous studies were only able to document a
trend towards significance [32, 33, 35].
Immunotherapy in Endometrial Cancer
Therapeutic Vaccination
Therapeutic cancer vaccination is a form of active im-
munotherapy (Table 2). Active immunotherapies stimu-
late the host’s own immune system to mount an anti-
tumor immune response and induce immunological
memory, theoretically producing a durable effect after
treatment is stopped. Cancer vaccines exploit the cellu-
lar arm of the immune system, inciting a cytotoxic T-
lymphocyte response against tumor-associated antigens
(TAAs). In concept, cancer vaccines offer the prospect
of high specificity, low toxicity, and prolonged activity,
though these properties have yet to be reliably translated
in clinical practice [40].
The product of Wilms tumor gene 1 (WT1) has been
identified as a TAA with therapeutic potential in endo-
metrial cancer. WT1 is located on chromosome 11p13
and encodes a transcription factor that plays an essential
role in the normal development of the urogenital system.
It has been detected in 0 % to 79 % of endometrial can-
cer, depending on the immunohistochemical staining
technique [41]. The safety and tolerability of a weekly
WT1 peptide vaccine (HLA-A2402-restricted, modified
9-mer WT1 peptide emulsified with Montanide ISA51
adjuvant) in 12 patients with recurrent or progressive
gynecologic malignancies was demonstrated in a recent
phase I trial [42]. Adverse events were limited to ery-
thema at the injection site, and the disease control rate
in the initial 3 months was 25 % (stable disease [SD] in 3
patients, progressive disease [PD] in 9 patients). Unfor-
tunately, the only subject with recurrent uterine carcino-
sarcoma failed to respond to treatment, with disease
progression after 11 vaccine injections (3 months on
therapy). Utilizing an alternative approach, Cooseman
and colleagues have reported the vaccination of 4 patients
with advanced serous endometrial cancer with autologous
dendritic cells loaded with WT1 mRNA [43, 44]. After 4
weekly injections, 3 of 4 patients demonstrated an im-
munological response (defined as an increase in the per-
centage of WT1-specific T-cells or NK cells among
peripheral blood mononuclear cells), 2 of 4 patients dem-
onstrated a molecular response (defined as a decrease in
CA-125), but no patients were found to have a decrease in
tumor size on repeat CT scan. Similar to the experience in
the WT1 peptide trial, adverse events were limited to
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erythema at the injection site and 1 local allergic reaction.
The investigators hypothesized that the limited clinical re-
sponse may be partially attributable to the advanced stage
of the patients and the early termination of therapy once
radiological progression was demonstrated.
Cancer testis (CT) antigens, expressed exclusively in male
germ cells and placental tissue in healthy adults but ectopi-
cally in tumor cells of multiple types of human cancer, have
emerged as excellent candidates for therapeutic manipula-
tion. The restricted nature of their expression lends to high
tumor-specificity and immunogenicity [45]. To date, several
CTantigens have been identified in endometrial cancer. NY-
ESO-1 and MAGE-A4 have been reported in 19 % and
12 % of endometrioid adenocarcinomas, respectively [46].
These numbers increase to 32 % and 63 % of USC, respect-
ively. Additionally, KU-CT-1 has been identified in 64 % of
cases of endometrial cancer [47] and SSX-4 in 24 % of cases
[48]. In a two-part, open-label cohort study designed to test
the safety and immunogenicity of recombinant vaccinia-NY-
ESO-1 and recombinant fowlpox-NY-ESO-1, 36 patients
with a wide range of tumor types experienced a similar,
minor reaction to the vaccine (erythema and pruritis at the
injection site) but differed significantly in their immunologic
response [49]. The sole patient with endometrial cancer was
Table 2 Immunotherapeutic approaches and their application to endometrial cancera
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one of three patients to demonstrate NY-ESO-1 sero-
conversion and both a CD8+ and CD4+ T-cell response.
Additionally, human epidermal growth factor receptor 2
(HER-2/neu), the transmembrane receptor encoded by the
ERBB2 gene, has exciting potential in the treatment of endo-
metrial cancer. In USC, specifically, overexpression of HER-
2/neu ranges from 16 % to 80 % and is associated with
worse overall survival [50–52]. The success of targeted ther-
apy with trastuzumab, a recombinant humanized monoclo-
nal antibody against HER2, in producing impressive
response rates and prolonged disease-free survival in pa-
tients with metastatic breast cancer [53, 54] has encouraged
the development of active immunotherapies that may pro-
duce a more durable anti-tumor immune response. In a
phase I, dose-escalating, safety trial in patients with various
metastatic, heavily pretreated cancers, Kaumaya and col-
leagues [55] tested a novel peptide combination vaccine
consisting of 2 B-cell epitopes derived from the HER2 extra-
cellular domain. In utilizing B-cell epitopes rather than T-
cell epitopes, they were able to overcome the requirement
for specific HLA restrictions in their patient population and
engage the humoral arm of the immune system. Between
the 2 endometrial cancer patients enrolled in the study, 1
patient has a partial response, experiencing extended clinical
benefit at 4 years after the initial vaccination. In functional
studies, the vaccine elicited antibodies in this patient that
disrupted 2 different HER2 signaling methods, ultimately
suppressing HER2 phosphorylation and inhibiting cell pro-
liferation. Vaccines such as this one offer hope that we may
overcome the limitations of antibody therapy, namely the
short half-life of IgG, requiring frequent treatments and ac-
cruing high costs.
Adoptive Cellular Therapy
Adoptive cellular therapy is a form of passive immunother-
apy (Table 2). Passive immunotherapies involve the adminis-
tration of immune system components (i.e. antibodies,
cytokines, lymphocytes) that are exogenously produced or
manipulated to promote an anti-tumor immune response.
Unable to induce immunological memory, they offer imme-
diate but short-term protection. In adoptive cellular therapy,
cells from the blood or bone marrow are isolated, activated
and expanded in vitro, and re-infused into the same patient
(autologous) or a different patient (allogeneic). The tech-
nology has evolved substantially and now includes the
generation of tumor-reactive T cells that are genetically
engineered to express recombinant or chimeric T-cell re-
ceptors directed against common TAAs (CAR T cells).
Adoptive cellular therapy in the treatment of endometrial
cancer has not yet exploited these most recent technological
advances. The earliest animal studies involved the infusion
of lymphokine-activated killer (LAK) cells with and without
additional immuno-stimulatory components (Il-2, lentinan)
[56, 57]. This therapy produced growth retardation of tumor
in nude mice. Intraperitoneal adoptive transfer of LAK cells
with IL-2 has also been tested in a phase I trial that enrolled
12 colorectal cancer patients, 10 ovarian cancer patients,
and 1 endometrial cancer patient with abdominal metastases
[58]. Thirty percent of patients had a laparoscopy- or
laparotomy-documented PR, though this did not include
the patient with endometrial cancer. While the majority of
adverse events (minor to moderate hypotension, fever,
chills, rash, nausea, vomiting, abdominal pain and disten-
sion, diarrhea, oliguria, fluid retention, thrombocytopenia,
and minor elevations of liver function tests) were attribut-
able to Il-2, intraperitoneal fibrosis (14 patients) was a not-
able toxic side effect of the therapy that led to treatment
discontinuation in 5 patients. Adding to the question of
safety, one patient had a grand mal seizure and another
had colonic perforation.
The infusion of peripheral blood T cells stimulated with
tumor lysate-pulsed autologous dendritic cells has been re-
ported by Santin and colleagues [59] in a 65-year-old patient
with advanced, chemoresistant endometrial cancer. Prior to
the treatment, which consisted of 3 infusions administered
every 3 to 4 weeks, the patient’s liver metastasis had sub-
stantially increased in size (9.5 X 8 cm to 14 X 10 cm in
3 weeks). During treatment, stabilization of the liver metas-
tasis was achieved as a result of a tumor-specific, cytotoxic
T-cell response. A more dramatic response was likely lim-
ited by the inability of the activated T cells to deeply infil-
trate the large tumor mass, as evaluated in 3 dimensions by
single photon emission computerized tomography (SPECT)
imaging. Since publication of this report, these investigators
have also demonstrated the ability to induce a tumor-
specific, cytotoxic T-cell response in vitro through vaccin-
ation with tumor lysate-pulsed autologous dendritic cells in
3 patients with USC [60].
Bispecific T-cell Engager (BiTE) Antibodies
The diverse array of molecules employed within passive im-
munotherapeutic approaches now includes bispecific T-cell
engager (BiTE) antibodies [61]. These novel molecules in-
duce a transient cytolytic synapse between a cytotoxic T cell
and the cancer target cell. This interaction results in dis-
charge of cytotoxic T-cell contents following perforin fusion
with the T-cell membrane resulting in direct tumor cell lysis.
Currently, the only drug within this class with United States
FDA approval is blinatumomab (BiTE for CD 19 and CD3)
for patients with acute lymphoblastic leukemia (ALL), based
on an impressive complete remission rate in a phase 2 clin-
ical trial [62].
Solitomab, which targets epithelial-cell-adhesion-molecule
(EpCAM) on tumor cells while also containing a CD3 bind-
ing region, is being pursued as treatment for metastatic, re-
current, or persistent USC overexpressing EpCAM (86 % of
USC cell lines tested by flow cytometry) [63]. After exposure
to peripheral blood lymphocytes in vitro, EpCAM positive
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USC cells were found to be resistant to NK or T-cell-
mediated killing. This resistance was overcome by incubat-
ing the cell lines with solitomab. Additionally, ex vivo incu-
bation of autologous tumor associated lymphocytes (TAL)
with EpCAM expressing malignant cells in ascites with soli-
tomab resulted in a significant increase in both CD4+ and
CD8+ T-cell proliferation, an increase in T-cell activation
markers, and a reduction in number of viable USC cells in
ascites.
Immune Checkpoint Inhibitors
The therapies discussed thus far involve activating the im-
mune system to achieve tumor cell death. However, recog-
nition that the effectiveness of both active and passive
immunotherapies are reduced by tumor immune evasion
[40] has led to a recent paradigm shift within immuno-
therapeutics away from a focus on stimulating the im-
mune system to a focus on inhibiting the inhibitors of an
adequate immune response. Among the emerging strat-
egies of tackling immune tolerance, immune checkpoint
inhibitors are the most promising.
Immune checkpoints refer to a variety of inhibitory path-
ways employed by the immune system to maintain self-
tolerance and minimize collateral damage during physio-
logic responses to pathogens. Many of these pathways are
initiated by ligand-receptor interactions on the surface of
immune cells and, thus, are logical targets for monoclonal
antibodies. Cytotoxic T-lymphocyte-associated protein-4
(CTLA-4) and programmed cell death protein-1 (PD-1)
were the first, and remain the most relevant, immune-
checkpoint receptors to be clinically targeted [64]. Although
PD-1 and CTLA-4 belong to the same CD28 family of T-
cell receptors, they assume very different roles in the down
regulation of an inflammatory response. While CTLA-4 pre-
dominately regulates T cell activation within secondary
lymphoid organs, PD-1 predominately regulates T cell ef-
fector function within peripheral tissues.
Importantly, immunohistochemical studies on endomet-
rial cancer specimens have detailed PD-1 and PD-L1 ex-
pression levels surpassing those seen in ovarian and
cervical carcinoma. Specifically, Vanderstraeten et al. de-
scribed PD-L1 expression levels of 67-100 % in primary,
recurrent and metastatic endometrial cancer specimens
[29]. At the 2015 annual meeting of the Society of Gyne-
cologic Oncology, Herzog et al. reported PD-1 expression
levels of 75 %, and PD-L1 expression levels ranging from
25-47 %, once again surpassing all examined cervical and
ovarian cancer specimens [65] (Table 3). Given the above,
investigation of immune checkpoint inhibitors in patients
with metastatic and recurrent endometrial cancer may
represent a promising alternative to traditional cytotoxic
therapies.
While preliminary evidence exists that tumor cell surface
PD-L1 expression correlates with the likelihood of response
to PD-1 pathway inhibition [66], the best argument for the
use of checkpoint inhibitors in select endometrial cancer
cases was recently put forth by a phase 2 trial of pembroli-
zumab, a humanized monoclonal antibody to the PD-1 re-
ceptor, in patients with mismatch repair- (MMR-) deficient
tumors [67]. This trial was designed to test the hypothesis
that MMR-deficient tumors are more responsive to PD-1
blockade than MMR-proficient tumors, due to the high
somatic mutational load, resulting in neoantigen formation
and a more prominent lymphocytic infiltrate. As predicted,
the two cohorts with MMR-deficient cancers (one with
colorectal cancer patients and the other with non-colorectal
cancer patients, including 2 patients with endometrial can-
cer) had significantly higher objective response rates by
immune-related response criteria and by Response Evalu-
ation Criteria in Solid Tumors (RECIST). They also had a
significantly better immune-related PFS at 20 weeks and dis-
ease control rate by RECIST. Interestingly, patients with
sporadic MMR-deficient tumors responded more frequently
to treatment than those with Lynch syndrome (100 % vs
27 %). This study provides preliminary clinical evidence that
immune checkpoint inhibitors may be used effectively in the
treatment of MMR-deficient endometrial cancers, and trials
exploring this hypothesis are currently in development.
More recently, Howitt et al. specifically examined the
hypothesis that microsatellite unstable endometrial can-
cers would exhibit more tumor specific neoantigens,
resulting in increased tumor infiltrating lymphocytes
and a compensatory up-regulation of immune check-
points (9). Microsatellite unstable tumors exhibited
higher numbers of CD3+ and CD8+ tumor infiltrating
lymphocytes. Furthermore, PD-1 was overexpressed in
tumor infiltrating lymphocytes, and peri-tumoral lym-
phocytes of microsatellite unstable tumors.
Conclusion
Despite existing evidence that endometrial cancer, particu-
larly the most aggressive forms of the disease, is sufficiently
immunogenic to be a reasonable candidate for immunomo-
dulation, attempts to expand the role of active and/or pas-
sive immunotherapy in the treatment of this condition have
Table 3 PD-1 and PD-L1 expression levels in uterine cancer
(450 specimens) [67]
Histology PD-1 PD-L1
% Expression based on IHC staining*
Endometrioid 77.9 39.7
Serous Carcinoma 68.2 10.2
Carcinosarcoma 80.0 22.2
Leiomyosarcoma 46.9 36.0
Stromal Sarcoma 64.3 64.3
Clear Cell Carcinoma 69.2 23.1
* IHC antibody = Spring Bioscience (Rabbit anti-Human IgG)
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been limited. At a time when the U.S. FDA-approved indica-
tions for immune checkpoint inhibitors is steadily amassing,
progress in the endometrial cancer arena has been slow.
Uniquely, endometrial cancer is the only gynecologic cancer
with a rising incidence and mortality, and identifying effect-
ive therapies for patient with metastatic or recurrent disease
is critical.
As reviewed here, these patients have been enrolled in
small preclinical and phase I trials assessing the utility of im-
munotherapy. These studies have demonstrated encour-
aging immunologic responses but few clinical responses,
provoking questions regarding the ability to establish thera-
peutic efficacy in a small number of heavily pretreated pa-
tients with advanced disease and short follow-up. The most
urgent questions in identifying the utility of immunotherapy
for the treatment of endometrial cancer are: how do we
identify the subset of individuals most likely to respond to
immunotherapy, the biomarkers most likely to predict suc-
cessful treatment, and the therapy combinations most likely
to enhance drug performance while limiting toxicity.
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